These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20882002)

  • 1. HIV: Antibodies with a split personality.
    Plückthun A
    Nature; 2010 Sep; 467(7315):537-8. PubMed ID: 20882002
    [No Abstract]   [Full Text] [Related]  

  • 2. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.
    Mouquet H; Scheid JF; Zoller MJ; Krogsgaard M; Ott RG; Shukair S; Artyomov MN; Pietzsch J; Connors M; Pereyra F; Walker BD; Ho DD; Wilson PC; Seaman MS; Eisen HN; Chakraborty AK; Hope TJ; Ravetch JV; Wardemann H; Nussenzweig MC
    Nature; 2010 Sep; 467(7315):591-5. PubMed ID: 20882016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains.
    Chuang GY; Acharya P; Schmidt SD; Yang Y; Louder MK; Zhou T; Kwon YD; Pancera M; Bailer RT; Doria-Rose NA; Nussenzweig MC; Mascola JR; Kwong PD; Georgiev IS
    J Virol; 2013 Sep; 87(18):10047-58. PubMed ID: 23843642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.
    McGuire AT; Dreyer AM; Carbonetti S; Lippy A; Glenn J; Scheid JF; Mouquet H; Stamatatos L
    Science; 2014 Dec; 346(6215):1380-1383. PubMed ID: 25504724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
    Schoofs T; Barnes CO; Suh-Toma N; Golijanin J; Schommers P; Gruell H; West AP; Bach F; Lee YE; Nogueira L; Georgiev IS; Bailer RT; Czartoski J; Mascola JR; Seaman MS; McElrath MJ; Doria-Rose NA; Klein F; Nussenzweig MC; Bjorkman PJ
    Immunity; 2019 Jun; 50(6):1513-1529.e9. PubMed ID: 31126879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
    Chuang GY; Geng H; Pancera M; Xu K; Cheng C; Acharya P; Chambers M; Druz A; Tsybovsky Y; Wanninger TG; Yang Y; Doria-Rose NA; Georgiev IS; Gorman J; Joyce MG; O'Dell S; Zhou T; McDermott AB; Mascola JR; Kwong PD
    J Virol; 2017 May; 91(10):. PubMed ID: 28275193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies.
    Zhu C; Dukhovlinova E; Council O; Ping L; Faison EM; Prabhu SS; Potter EL; Upton SL; Yin G; Fay JM; Kincer LP; Spielvogel E; Campbell SL; Benhabbour SR; Ke H; Swanstrom R; Dokholyan NV
    Nat Commun; 2019 Feb; 10(1):948. PubMed ID: 30814513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans.
    Garces F; Lee JH; de Val N; de la Pena AT; Kong L; Puchades C; Hua Y; Stanfield RL; Burton DR; Moore JP; Sanders RW; Ward AB; Wilson IA
    Immunity; 2015 Dec; 43(6):1053-63. PubMed ID: 26682982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited conformational flexibility in the paratope may be responsible for degenerate specificity of HIV epitope recognition.
    Bhowmick A; Salunke DM
    Int Immunol; 2013 Feb; 25(2):77-90. PubMed ID: 22968994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
    Leaman DP; Lee JH; Ward AB; Zwick MB
    J Virol; 2015 Jul; 89(13):6725-45. PubMed ID: 25878116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV: conformational camouflage.
    Jardetzky T
    Nature; 2002 Dec; 420(6916):623-4. PubMed ID: 12478278
    [No Abstract]   [Full Text] [Related]  

  • 13. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?
    Alexander MR; Ringe R; Sanders RW; Voss JE; Moore JP; Klasse PJ
    J Virol; 2015 Jun; 89(11):5981-95. PubMed ID: 25810537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies.
    Torrents de la Peña A; Sanders RW
    Retrovirology; 2018 Sep; 15(1):63. PubMed ID: 30208933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].
    Granados-González V; Piedrahita LD; Martínez M; Genin C; Riffard S; Urcuqui-Inchima S
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):523-30. PubMed ID: 19409660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env.
    Kwon YD; Pancera M; Acharya P; Georgiev IS; Crooks ET; Gorman J; Joyce MG; Guttman M; Ma X; Narpala S; Soto C; Terry DS; Yang Y; Zhou T; Ahlsen G; Bailer RT; Chambers M; Chuang GY; Doria-Rose NA; Druz A; Hallen MA; Harned A; Kirys T; Louder MK; O'Dell S; Ofek G; Osawa K; Prabhakaran M; Sastry M; Stewart-Jones GB; Stuckey J; Thomas PV; Tittley T; Williams C; Zhang B; Zhao H; Zhou Z; Donald BR; Lee LK; Zolla-Pazner S; Baxa U; Schön A; Freire E; Shapiro L; Lee KK; Arthos J; Munro JB; Blanchard SC; Mothes W; Binley JM; McDermott AB; Mascola JR; Kwong PD
    Nat Struct Mol Biol; 2015 Jul; 22(7):522-31. PubMed ID: 26098315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.